Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.21 USD | +0.72% | -7.27% | +29.94% |
Financials (USD)
Sales 2024 * | 833K | Sales 2025 * | 4.6M | Capitalization | 331M |
---|---|---|---|---|---|
Net income 2024 * | -127M | Net income 2025 * | -136M | EV / Sales 2024 * | 322 x |
Net cash position 2024 * | 61.98M | Net cash position 2025 * | 61.76M | EV / Sales 2025 * | 58.4 x |
P/E ratio 2024 * |
-2.68
x | P/E ratio 2025 * |
-2.68
x | Employees | 140 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.29% |
Latest transcript on Tenaya Therapeutics, Inc.
1 day | +0.72% | ||
1 week | -7.27% | ||
1 month | -7.27% | ||
3 months | -29.24% | ||
6 months | +123.94% | ||
Current year | +29.94% |
Managers | Title | Age | Since |
---|---|---|---|
Faraz Ali
CEO | Chief Executive Officer | 51 | 18-05-31 |
Leone Patterson
DFI | Director of Finance/CFO | 61 | 21-05-31 |
Kee-Hong Kim
CTO | Chief Tech/Sci/R&D Officer | - | 18-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Williams
BRD | Director/Board Member | 75 | 16-09-30 |
David Goeddel
CHM | Chairman | 72 | 16-07-31 |
Jeffrey Walsh
BRD | Director/Board Member | 58 | 20-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +3.86% | - | |
0.00% | 17 M€ | +4.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 4.21 | +0.72% | 301,019 |
24-05-30 | 4.18 | +1.95% | 448,075 |
24-05-29 | 4.1 | -0.97% | 315,147 |
24-05-28 | 4.14 | -8.81% | 331,015 |
24-05-24 | 4.54 | +4.13% | 262,024 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.94% | 331M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- TNYA Stock